Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar 2;110(3):419-426.
doi: 10.1016/j.ajhg.2023.01.018.

Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare

Affiliations
Review

Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare

Zornitza Stark et al. Am J Hum Genet. .

Abstract

Australian Genomics is a national collaborative partnership of more than 100 organizations piloting a whole-of-system approach to integrating genomics into healthcare, based on federation principles. In the first five years of operation, Australian Genomics has evaluated the outcomes of genomic testing in more than 5,200 individuals across 19 rare disease and cancer flagship studies. Comprehensive analyses of the health economic, policy, ethical, legal, implementation and workforce implications of incorporating genomics in the Australian context have informed evidence-based change in policy and practice, resulting in national government funding and equity of access for a range of genomic tests. Simultaneously, Australian Genomics has built national skills, infrastructure, policy, and data resources to enable effective data sharing to drive discovery research and support improvements in clinical genomic delivery.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests R.L.W. is the Chair of the Medical Services Advisory Committee; the views in this paper are not representing those of the Commonwealth of Australia. I.E.S. has served on scientific advisory boards for BioMarin, Chiesi, Eisai, Encoded Therapeutics, GlaxoSmithKline, Knopp Biosciences, Nutricia, Rogcon, Takeda Pharmaceuticals, UCB, and Xenon Pharmaceuticals; has received speaker honoraria from GlaxoSmithKline, UCB, BioMarin, Biocodex, Chiesi, Liva Nova, Nutricia, Zuellig Pharma, and Eisai; has received funding for travel from UCB, Biocodex, GlaxoSmithKline, Biomarin, and Eisai; has served as an investigator for Anavex Life Sciences, Cerecin Inc, Cerevel Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceuticals, Zogenix, and Zynerba; and has consulted for Care Beyond Diagnosis, Epilepsy Consortium, Atheneum Partners, Ovid Therapeutics, UCB, Zynerba Pharmaceuticals, BioMarin, Encoded Therapeutics, and Biohaven Pharmaceuticals; and is a Non-Executive Director of Bellberry Ltd and a Director of the Australian Academy of Health and Medical Sciences and the Australian Council of Learned Academies Limited. She may accrue future revenue on pending patent WO61/010,176 (filed: 2008): Therapeutic Compound; has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies; and has a patent molecular diagnostic/theranostic target for benign familial infantile epilepsy (BFIE) (PRRT2) 2,011,904,493 & 2,012,900,190 and PCT/AU2012/001,321 (TECH ID:2012-009).

Figures

Figure 1
Figure 1
Informing evidence-based implementation of genomic testing in rare disease and cancer (A) National recruitment sites, participant demographics, and willingness for data to be used for further research. (B and C) Diagnostic outcomes of genomic testing across (B) 13 rare disease and (C) 6 cancer studies.
Figure 2
Figure 2
The Australian landscape of national and state/territory-based policies, frameworks, and genomic initiatives National, orange; state/territory, blue. SA, South Australia; WA, Western Australia; OPHG, Office of Population Health Genomics; QLD, Queensland; VIC, Victoria; NSW, New South Wales.

Similar articles

Cited by

References

    1. Gaff C.L., M Winship I., M Forrest S., P Hansen D., Clark J., M Waring P., South M., H Sinclair A. Preparing for genomic medicine: a real world demonstration of health system change. NPJ Genom. Med. 2017;2:31. - PMC - PubMed
    1. Stark Z., Dolman L., Manolio T.A., Ozenberger B., Hill S.L., Caulfied M.J., Levy Y., Glazer D., Wilson J., Lawler M., et al. Integrating genomics into healthcare: a global responsibility. Am. J. Hum. Genet. 2019;104:13–20. - PMC - PubMed
    1. All of Us Research Program Investigators. Denny J.C., Rutter J.L., Goldstein D.B., Philippakis A., Smoller J.W., Jenkins G., Dishman E. The "All of Us" research program. N. Engl. J. Med. 2019;381:668–676. - PMC - PubMed
    1. Turnbull C., Scott R.H., Thomas E., Jones L., Murugaesu N., Pretty F.B., Halai D., Baple E., Craig C., Hamblin A., et al. The 100 000 Genomes Project: bringing whole genome sequencing to the NHS. BMJ. 2018;361:k1687. - PubMed
    1. Fatumo S., Yakubu A., Oyedele O., Popoola J., Attipoe D.A., Eze-Echesi G., Modibbo F.Z., Ado-Wanka N., et al. 54gene Team. NCD-GHS Consortium Promoting the genomic revolution in Africa through the Nigerian 100K Genome Project. Nat. Genet. 2022;54:531–536. - PubMed

Publication types

LinkOut - more resources